{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:55:07Z","timestamp":1793372107696,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["216593\/Z\/19\/Z"],"award-info":[{"award-number":["216593\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ophtha.2022.06.042","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T21:48:40Z","timestamp":1657748920000},"page":"1389-1401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"129","author":[{"given":"Emer","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep S.","family":"Josan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanmin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2022.06.042_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.ophtha.2022.06.042_bib3","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2022.06.042_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.06.042_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013344","article-title":"Anaesthesia modalities during laser photocoagulation for retinopathy of prematurity: a retrospective, longitudinal study","volume":"7","author":"Jiang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2022.06.042_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2022.06.042_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129383","article-title":"A\u00a0systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2022.06.042_bib8","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmarcokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2022.06.042_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib13","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2022.06.042_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib16","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2022.06.042_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-020-00276-3","article-title":"Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors","volume":"7","author":"Bazvand","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2022.06.042_bib19","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0057","article-title":"Concerns for development after bevacizumab treatment of ROP","volume":"137","author":"Quinn","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2022.06.042_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: An introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ophtha.2022.06.042_bib76","article-title":"Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022).","author":"Chaimani","year":"2022","journal-title":"Cochrane"},{"key":"10.1016\/j.ophtha.2022.06.042_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2022.06.042_bib22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib23","unstructured":"Chiang MF, Quinn GE, Fielder AR, et\u00a0al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128:e51\u2013e68."},{"key":"10.1016\/j.ophtha.2022.06.042_bib24","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/s41433-020-01321-z","article-title":"Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity","volume":"35","author":"Mori","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2022.06.042_bib26","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.ophtha.2022.06.042_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ophtha.2022.06.042_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1027\/2151-2604\/a000392","article-title":"Power-enhanced funnel plots for meta-analysis: the sunset funnel plot","volume":"228","author":"Kossmeier","year":"2020","journal-title":"Zeitschrift f\u00fcr Psychologie"},{"key":"10.1016\/j.ophtha.2022.06.042_bib30","author":"van Valkenhoef"},{"key":"10.1016\/j.ophtha.2022.06.042_bib31","author":"van Valkenhoef"},{"key":"10.1016\/j.ophtha.2022.06.042_bib32","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2022.06.042_bib33","author":"Wells"},{"key":"10.1016\/j.ophtha.2022.06.042_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2022.06.042_bib35","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1055\/s-0040-1710556","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","volume":"38","author":"Zayek","year":"2021","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib37","first-page":"290","article-title":"Evaluation of treatment models in the treatment of retinopathy of prematurity","volume":"53","author":"Demir","year":"2019","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"10.1016\/j.ophtha.2022.06.042_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib39","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib40","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis","volume":"22","author":"Nicoar\u0103","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ophtha.2022.06.042_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.06.042_bib42","first-page":"13","article-title":"Comparison of ocular and developmental outcomes in laser and bevacizumab-treated infants with retinopathy of prematurity","volume":"3","author":"Kong","year":"2015","journal-title":"Ophthalmol Res"},{"key":"10.1016\/j.ophtha.2022.06.042_bib43","first-page":"140","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"JAAPOS"},{"key":"10.1016\/j.ophtha.2022.06.042_bib44","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41598-021-83985-5","article-title":"Management of retinopathy of prematurity (ROP) in a Polish cohort of infants","volume":"11","author":"Chmielarz-Czarnoci\u0144ska","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2022.06.042_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","article-title":"Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study","volume":"19","author":"Lyu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12886-018-0973-1","article-title":"The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units","volume":"18","author":"Leng","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/srep27082","article-title":"Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2022.06.042_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3928\/01913913-20191104-01","article-title":"Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"57","author":"Ekinci","year":"2020","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2022.06.042_bib50","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib51","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2022.06.042_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2022.06.042_bib53","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age","volume":"2018","author":"Chen","year":"2018","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000489023","article-title":"Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1","volume":"240","author":"Kimyon","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2022.06.042_bib56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-esfahani","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2022.06.042_bib60","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013366","article-title":"Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk","volume":"7","author":"Adams","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2022.06.042_bib62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3,701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyama\u00e7 Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2022.06.042_bib64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-620X.106103","article-title":"Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity","volume":"5","author":"Lin","year":"2012","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib65","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","volume":"32","author":"Stewart","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.06.042_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ophtha.2022.06.042_bib67","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.06.042_bib68","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib69","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ophtha.2022.06.042_bib71","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2022.06.042_bib72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.06.042_bib73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","article-title":"Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities","volume":"4","author":"Cameron","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.ophtha.2022.06.042_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.ophtha.2022.06.042_bib75","first-page":"975","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"0","author":"Wu","year":"2021","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202200522X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202200522X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:12:40Z","timestamp":1758982360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202200522X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S016164202200522X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.06.042","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}